First To Know Pregnancy Test - Clinical Evaluation Protocol
NCT ID: NCT07304531
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1705 participants
OBSERVATIONAL
2025-10-14
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The clinical evaluation includes lay users self-testing and additional blood being drawn for comparator testing. All negative test results will be followed up for outcome. All subjects with positive test results or reporting negative results later resulted in pregnancy will be confirmed by obtaining data from standard of care assessment(s) for diagnosis of pregnancy.
Two (2) cohorts are planned to assess:
Cohort A: Cross sectional cohort evaluating clinical performance with enrollment up to 100 pregnant subjects across three (3) age groups conducted at clinical sites. Tests will be read and interpreted by the lay user. Blood will be collected at the time of testing for comparator method testing. Positive test results will be confirmed by obtaining data from standard of care assessment(s) for diagnosis of pregnancy.
Cohort A1: pre-menopausal women age 14-40
Cohort A2: peri-menopausal women age 41-55
Cohort A3: post-menopausal women age \>55
Cohort B: Duplicate testing cohort designed to evaluate accuracy and precision in lay users. A subset of a minimum of 100 participants from Cohort A will co-enroll into Cohort B and conduct duplicate testing using the First To Know® Pregnancy test. Participants will independently self-administer two tests consecutively and visually interpret the results without assistance.
Enrollment will reflect the observed prevalence of positive and negative pregnancy results in Cohort A, ensuring adequate representation across all age cohorts (pre-menopausal, peri-menopausal, and post-menopausal). The results from the first test will be used to assess accuracy, while the second test will evaluate precision and agreement with the first test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A1 - Pre-menopausal women ages 14-40
Participants must be a mixture of English and Spanish speaking, geographically diverse, ethnically and racially diverse, economically diverse, and with different levels of educations, ages 14-40
Diagnostic Test
For this observational trial , the Intervention of interest is the First To Know Pregnancy Test
Cohort A2 - Peri-menopausal women ages 41-55
Participants must be a mixture of English and Spanish speaking, geographically diverse, ethnically and racially diverse, economically diverse, and with different levels of educations, ages 41-55
Diagnostic Test
For this observational trial , the Intervention of interest is the First To Know Pregnancy Test
Cohort A3 - Post-menopausal women ages >55
Participants must be a mixture of English and Spanish speaking, geographically diverse, ethnically and racially diverse, economically diverse, and with different levels of educations, age over 55
Diagnostic Test
For this observational trial , the Intervention of interest is the First To Know Pregnancy Test
Cohort B1 - Subset of Cohort A1 Pre-menopausal women ages 14-40
Participants must be a mixture of English and Spanish speaking, geographically diverse, ethnically and racially diverse, economically diverse, and with different levels of educations, ages 14-40
Diagnostic Test
For this observational trial , the Intervention of interest is the First To Know Pregnancy Test
Cohort B1 - Subset of Cohort A2 - Peri-menopausal women ages 41-55
Participants must be a mixture of English and Spanish speaking, geographically diverse, ethnically and racially diverse, economically diverse, and with different levels of educations, ages 41-55
Diagnostic Test
For this observational trial , the Intervention of interest is the First To Know Pregnancy Test
Cohort B3 - Subset of Cohort A3 - Post-menopausal women ages >55
Participants must be a mixture of English and Spanish speaking, geographically diverse, ethnically and racially diverse, economically diverse, and with different levels of educations, age over 55
Diagnostic Test
For this observational trial , the Intervention of interest is the First To Know Pregnancy Test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnostic Test
For this observational trial , the Intervention of interest is the First To Know Pregnancy Test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age Selection - must meet one of the following age groups:
* Cohort A1 - Pre-menopausal: ≥14 years of age and ≤ 40 years of age with menstrual cycles (cycle lengths of 25-35 days)
* Cohort A2 - Peri-menopausal: ≥41 years of age and ≤ 54 years of age
* Cohort A3 - Post-menopausal: ≥55 years of age
* Not menstruating at the time of the initial study visit
* Must be willing to complete all study activities, provide all specimens/samples, and conduct all required testing
* Willing to provide information regarding the diagnosis of pregnancy or details from their standard of care follow-up visit after initial visit
* Sexually active
* Not using contraceptives
* English/Spanish speaking
Exclusion Criteria
* Females \<14 years of age
* Recent pregnancy within the past 6 months
* Trophoblastic disease or non-trophoblastic neoplasms
* Downs syndrome (trisomy 21)
* People with limited or no reading skills
* Amenorrhea not related to peri or post menopause
* Use of medications or hormonal contraceptives that may interfere with hCG levels at the time of testing (e.g., Gonadotropins: Luteinizing hormone)
14 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MCRA
INDUSTRY
NOWDiagnostics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Matrix Clinical Research Los Angeles
Los Angeles, California, United States
ERA Health Research
Midland, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Stan Gershovich
Role: primary
Ivette Cabrera
Role: backup
Hinali Zaveri, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-STDY-8001-01
Identifier Type: -
Identifier Source: org_study_id